Expanding exemptions for generics
The Hatch-Waxman Act in the US represented a careful balance of interests between the generic and brand name pharmaceutical manufacturers. William Feiler and Paula Wittmayer examine the Safe Harbor exemption and the challenges it represents to the biotech industry
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: